$16.56
0.422.6%
Last update: Nov 3, 4:02 PM
Aurinia Pharmaceuticals Inc
AUPHNASDAQ
Aurinia Pharmaceuticals (AUPH) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Aurinia Pharmaceuticals (AUPH) last issued guidance on October 30, 2026 for fiscal year 2026. The company guided revenue in the range of $325M - $330M for the period.
Compared to prior guidance, Aurinia Pharmaceuticals raised its revenue forecast from a prior range of $315M - $325M.
Aurinia Pharmaceuticals has issued 15 guidance updates between January 6, 2023 and October 30, 2026. During this period, the company raised its outlook 10 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.22 | $0.24 | $0.19 | $0.21 |
| Actual | $0.23 | $0.28 | $0.25 | $0.26 |
| Surprise | +4.55% | +16.7% | +31.6% | +23.8% |
| Revenue | ||||
| Estimate | $84.3M | $80.8M | $77.1M | $74.6M |
| Actual | $83.7M | $83.2M | $77.7M | $77.1M |
| Surprise | -0.74% | +2.97% | +0.83% | +3.40% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $0.21 | $0.19 |
| Revenue | ||
| Consensus | $86.1M | $83.0M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 30, 2026 | $0.23 | $0.22 | 4.55 % |
| Q2 | Aug 6, 2026 | $0.28 | $0.24 | 16.7 % |
| Q1 | May 7, 2026 | $0.25 | $0.19 | 31.6 % |
| Q4 | Feb 26, 2026 | $0.26 | $0.21 | 23.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Oct 30, 2026 | $83.70M | $84.33M | -0.74 % |
| Q2 | Aug 6, 2026 | $83.22M | $80.82M | 2.97 % |
| Q1 | May 7, 2026 | $77.71M | $77.06M | 0.83 % |
| Q4 | Feb 26, 2026 | $77.11M | $74.58M | 3.40 % |
